Angiogenin up-regulation correlates with adverse clinicopathological and biological factors, increased microvascular density and poor patient outcome in neuroblastomas

Histopathology

Volumn 60, Issue 6, 2012, Pages 911-923

  Dungwa, Josiah V ^a,b   Uparkar, Urmila ^a   May, Margaret T ^b   Ramani, Pramila ^a,b  

^a UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Angiogenesis; Angiogenin; CD31; Enzyme linked immunosorbent assay; Immunohistochemistry; Microvascular density; Neuroblastoma

Indexed keywords

ANGIOGENIN; CD31 ANTIGEN;

ADULT; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CHILD; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENT FREE SURVIVAL; FEMALE; GANGLIONEUROMA; GENE DELETION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UPREGULATION;

ABDOMINAL NEOPLASMS; ADOLESCENT; ANGIOGENESIS INDUCING AGENTS; ANTIGENS, CD31; CHILD; CHILD, PRESCHOOL; GANGLIONEUROMA; GREAT BRITAIN; HUMANS; INFANT; INFANT, NEWBORN; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PROGNOSIS; RIBONUCLEASE, PANCREATIC; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84860298399     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04176.x     Document Type: Article

References (45)

1. Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 2010; 29; 1566-1579.
2. Pastorino F, Di PD, Loi M et al. Recent advances in targeted anti-vasculature therapy: the neuroblastoma model. Curr. Drug Targets 2009; 10; 1021-1027.
3. Rossler J, Taylor M, Geoerger B et al. Angiogenesis as a target in neuroblastoma. Eur. J. Cancer 2008; 44; 1645-1656.
4. Maris JM, Courtright J, Houghton PJ et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008; 50; 581-587.
5. Maris JM, Courtright J, Houghton PJ et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008; 51; 42-48.
6. Peiris-Pages M, Harper SJ, Bates DO, Ramani P. Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth. J. Pathol. 2010; 222; 138-147.
7. Sims TL, Williams RF, Ng CY, Rosati SF, Spence Y, Davidoff AM. Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery 2008; 144; 269-275.
8. Zaghloul N, Hernandez SL, Bae JO et al. Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. Int. J. Oncol. 2009; 34; 401-407.
9. Strydom DJ, Fett JW, Lobb RR et al. Amino acid sequence of human tumor derived angiogenin. Biochemistry 1985; 24; 5486-5494.
10. Gao X, Xu Z. Mechanisms of action of angiogenin. Acta Biochim. Biophys. Sin. (Shanghai) 2008; 40; 619-624.
11. Fett JW, Strydom DJ, Lobb RR et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985; 24; 5480-5486.
12. Tsuji T, Sun Y, Kishimoto K et al. Angiogenin is translocated to the nucleus of HeLa cells and is involved in ribosomal RNA transcription and cell proliferation. Cancer Res. 2005; 65; 1352-1360.
13. Tello-Montoliu A, Patel JV, Lip GY. Angiogenin: a review of the pathophysiology and potential clinical applications. J. Thromb. Haemost. 2006; 4; 1864-1874.
14. Marioni G, Marino F, Blandamura S et al. Neoangiogenesis in laryngeal carcinoma: angiogenin and CD105 expression is related to carcinoma recurrence rate and disease-free survival. Histopathology 2010; 57; 535-543.
15. Chen Y, Zhang S, Chen YP, Lin JY. Increased expression of angiogenin in gastric carcinoma in correlation with tumor angiogenesis and proliferation. World J. Gastroenterol. 2006; 12; 5135-5139.
16. Hisai H, Kato J, Kobune M et al. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin. Cancer Res. 2003; 9; 4852-4859.
17. Olson KA, Fett JW, French TC, Key ME, Vallee BL. Angiogenin antagonists prevent tumor growth in vivo. Proc. Natl Acad. Sci. USA 1995; 92; 442-446.
18. Yoshioka N, Wang L, Kishimoto K, Tsuji T, Hu GF. A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc. Natl Acad. Sci. USA 2006; 103; 14519-14524.
19. Shimoyama S, Gansauge F, Gansauge S, Negri G, Oohara T, Beger HG. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res. 1996; 56; 2703-2706.
20. Shimoyama S, Yamasaki K, Kawahara M, Kaminishi M. Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin. Cancer Res. 1999; 5; 1125-1130.
21. Hartmann A, Kunz M, Kostlin S et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res. 1999; 59; 1578-1583.
22. Nakamura M, Yamabe H, Osawa H et al. Hypoxic conditions stimulate the production of angiogenin and vascular endothelial growth factor by human renal proximal tubular epithelial cells in culture. Nephrol. Dial. Transplant. 2006; 21; 1489-1495.
23. Pilch H, Schlenger K, Steiner E, Brockerhoff P, Knapstein P, Vaupel P. Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts. Int. J. Gynecol. Cancer 2001; 11; 137-142.
24. Rajashekhar G, Loganath A, Roy AC, Chong SS, Wong YC. Hypoxia up-regulated angiogenin and down-regulated vascular cell adhesion molecule-1 expression and secretion in human placental trophoblasts. J. Soc. Gynecol. Investig. 2005; 12; 310-319.
25. Sebastia J, Kieran D, Breen B et al. Angiogenin protects motoneurons against hypoxic injury. Cell Death Differ. 2009; 16; 1238-1247.
26. Campo L, Turley H, Han C et al. Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. J. Pathol. 2005; 205; 585-591.
27. Cho GW, Kang BY, Kim SH. Human angiogenin presents neuroprotective and migration effects in neuroblastoma cells. Mol. Cell. Biochem. 2010; 340; 133-141.
28. Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 1993; 11; 1466-1477.
29. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999; 86; 349-363.
30. Vermeulen PB, Gasparini G, Fox SB et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur. J. Cancer 2002; 38; 1564-1579.
31. Peddinti R, Zeine R, Luca D et al. Prominent microvascular proliferation in clinically aggressive neuroblastoma. Clin. Cancer Res. 2007; 13; 3499-3506.
32. Hu G, Xu C, Riordan JF. Human angiogenin is rapidly translocated to the nucleus of human umbilical vein endothelial cells and binds to DNA. J. Cell. Biochem. 2000; 76; 452-462.
33. Moroianu J, Riordan JF. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc. Natl Acad. Sci. USA 1994; 91; 1677-1681.
34. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene 2010; 29; 1249-1259.
35. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2009; 29; 625-634.
36. Kishimoto K, Liu S, Tsuji T, Olson KA, Hu GF. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 2005; 24; 445-456.
37. Soncin F. Angiogenin supports endothelial and fibroblast cell adhesion. Proc. Natl Acad. Sci. USA 1992; 89; 2232-2236.
38. Hu G, Riordan JF, Vallee BL. Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc. Natl Acad. Sci. USA 1994; 91; 12096-12100.
39. Jimi S, Ito K, Kohno K et al. Modulation by bovine angiogenin of tubular morphogenesis and expression of plasminogen activator in bovine endothelial cells. Biochem. Biophys. Res. Commun. 1995; 211; 476-483.
40. Shapiro R, Riordan JF, Vallee BL. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry 1986; 25; 3527-3532.
41. Shapiro R, Vallee BL. Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin. Alanine derivatives inhibit angiogenin-induced angiogenesis. Biochemistry 1989; 28; 7401-7408.
42. Hu GF, Riordan JF. Angiogenin enhances actin acceleration of plasminogen activation. Biochem. Biophys. Res. Commun. 1993; 197; 682-687.
43. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol. 1996; 14; 405-414.
44. Ozer E, Altungoz O, Unlu M, Aygun N, Tumer S, Olgun N. Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity. Appl. Immunohistochem. Mol. Morphol. 2007; 15; 181-186.
45. Ribatti D, Raffaghello L, Pastorino F et al. Invivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. Int. J. Cancer 2002; 102; 351-354.